Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin in Impaired Glucose Tolerance
NCT01548651Phase 4Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2012
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in impaired glucose tolerance (IGT) comparing Saxagliptin with Placebo (2 arms). Primary endpoints: Myocardial Fat Content at 6 months and Hepatic Fat Content at 6 months. Started Feb 2012; status: terminated.
02
Drugs
saxagliptin
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT01548651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01548651.